[go: up one dir, main page]

MX2015005862A - Enriquecimiento de plasmablastos especificos de antigeno. - Google Patents

Enriquecimiento de plasmablastos especificos de antigeno.

Info

Publication number
MX2015005862A
MX2015005862A MX2015005862A MX2015005862A MX2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A
Authority
MX
Mexico
Prior art keywords
enrichment
plasmablastos
specific antigen
methods
antigen
Prior art date
Application number
MX2015005862A
Other languages
English (en)
Inventor
Henry Chiu
Ning Chai
Zhonghua Lin
Juan Zhang
Mercedesz Balazs
Wyne P Lee
Patrick J Lupardus
Lee R Swen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2015005862A publication Critical patent/MX2015005862A/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pulmonology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a métodos para el enriquecimiento de plasmablastos específicos de antígeno. Los métodos son útiles para la identificación de anticuerpos, incluyendo anticuerpos raros que reconocen más de un antígeno.
MX2015005862A 2012-11-13 2013-11-12 Enriquecimiento de plasmablastos especificos de antigeno. MX2015005862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725764P 2012-11-13 2012-11-13
PCT/US2013/069588 WO2014078280A1 (en) 2012-11-13 2013-11-12 Enrichment of antigen-specific plasmablasts

Publications (1)

Publication Number Publication Date
MX2015005862A true MX2015005862A (es) 2015-09-10

Family

ID=49640215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005862A MX2015005862A (es) 2012-11-13 2013-11-12 Enriquecimiento de plasmablastos especificos de antigeno.

Country Status (16)

Country Link
US (1) US20140134638A1 (es)
EP (1) EP2920300B1 (es)
JP (1) JP2015536145A (es)
KR (1) KR20150084831A (es)
CN (1) CN104822828A (es)
AR (1) AR093447A1 (es)
AU (1) AU2013344992A1 (es)
BR (1) BR112015009933A2 (es)
CA (1) CA2889266A1 (es)
HK (1) HK1213009A1 (es)
IL (1) IL238302A0 (es)
MX (1) MX2015005862A (es)
RU (1) RU2015116927A (es)
SG (1) SG11201503706TA (es)
WO (1) WO2014078280A1 (es)
ZA (1) ZA201502711B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3408288A2 (en) 2016-01-29 2018-12-05 Achaogen, Inc. Screening methods for identifying antibodies that bind cell surface epitopes
CN111988991B (zh) * 2018-04-26 2023-09-15 豪夫迈·罗氏有限公司 用于追踪动物种群中的动物的方法和系统
WO2023150760A2 (en) * 2022-02-04 2023-08-10 Cornell University Enrichment and characterization of rare circulating cells, including progenitor cells, from peripheral blood, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005796A1 (en) * 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5663481A (en) * 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
EP1079688A1 (en) * 1998-05-26 2001-03-07 Innogenetics N.V. Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
EP1838735A2 (en) * 2004-12-31 2007-10-03 Genentech, Inc. Polypeptides that bind br3 and uses thereof
DK2021463T3 (en) * 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
US8133727B2 (en) * 2008-11-21 2012-03-13 California Institute Of Technology In vitro human B lymphopoiesis culture system
WO2011008093A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2703485B1 (en) * 2011-03-30 2018-12-26 National University Corporation University Of Toyama Method for selecting plasma cells and plasmablasts, and method for producing target antigen-specific antibody
GB201212550D0 (en) * 2012-07-13 2012-08-29 Novartis Ag B cell assay

Also Published As

Publication number Publication date
AR093447A1 (es) 2015-06-10
CN104822828A (zh) 2015-08-05
CA2889266A1 (en) 2014-05-22
WO2014078280A1 (en) 2014-05-22
ZA201502711B (en) 2016-11-30
JP2015536145A (ja) 2015-12-21
HK1213009A1 (zh) 2016-06-24
SG11201503706TA (en) 2015-06-29
RU2015116927A (ru) 2017-01-10
BR112015009933A2 (pt) 2017-12-12
EP2920300B1 (en) 2018-09-12
IL238302A0 (en) 2015-06-30
US20140134638A1 (en) 2014-05-15
KR20150084831A (ko) 2015-07-22
AU2013344992A1 (en) 2015-05-14
EP2920300A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
NI201700167A (es) Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina
NI201400061A (es) Anticuerpos anti - phf - tau y sus usos
CL2016002455A1 (es) Anticuerpos multiespecíficos.
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2015016535A (es) Metodo de produccion para tagatosa.
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
MX366296B (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
UY34095A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
CR20160147A (es) Formulaciones de anticuerpos
BR112014019909A8 (pt) Processo para produção de compostos úteis como antagonistas do receptor de orexina-2
UY34537A (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CY1118893T1 (el) Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
UY34582A (es) Anticuerpos anti-cxcr3
EA201500234A1 (ru) Способ получения бензоксазинонов
AR096154A1 (es) Colorantes bisazoicos alcoxilados
BR112014027219A2 (pt) método
AR097668A1 (es) Colorante-polímero
TR201908795T4 (tr) Bi̇r şeki̇llendi̇ri̇lebi̇li̇r kütleni̇n şeki̇llendi̇ri̇lmesi̇ i̇çi̇n ci̇haz